Widely prescribed for weight loss and glycemic control, glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly scrutinized. However, a recent systematic review indicates that randomized controlled trials evaluating these drugs seldom assess dietary intake or diet quality.
Researchers analyzed 43 trials involving over 50,000 participants, examining studies on liraglutide, semaglutide, and tirzepatide. Of these numerous trials, only two, both in adults, reported on dietary intake. These studies noted reductions in overall energy intake and shifts in macronutrient distribution among participants receiving the medications alongside dietary guidance. The methodological quality of these dietary assessments, however, was rated as poor to acceptable.
This significant gap in reporting means that the precise influence of GLP-1 agonists on diet quality, nutrient intake, and subsequent chronic disease risk remains largely unexamined. The review authors emphasize the urgent need for high-quality research that incorporates validated dietary assessment methods as outcome measures in future trials to fully understand the nutritional implications of these popular therapies.